Wednesday, April 17, 2013
Northwest Biotherapeutics Inc., of Bethesda, Md., said its Phase III study testing DCVax personalized immune therapy in glioblastoma multiforme was "adopted" as a national priority trial in the UK.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.